Analytical method co-qualification: A strategy to enhance operaitonal efficiency and accelerate development timelines

Samsung Biologics is helping to define a new benchmark for analytical assurance in biomanufacturing.
Data-driven and designed to reinforce method robustness as well as detect performance drifts in time, Samsung Biologics’ assay performance monitoring (APM) program proactively strengthens regulatory compliance while minimizing batch release delays.
Explore more insights in our latest Q&A whitepaper.

Samsung Biologics is helping to define a new benchmark for analytical assurance in biomanufacturing.
Data-driven and designed to reinforce method robustness as well as detect performance drifts in time, Samsung Biologics’ assay performance monitoring (APM) program proactively strengthens regulatory compliance while minimizing batch release delays.
Explore more insights in our latest Q&A whitepaper.
Related Content